跳转至内容
Merck

SML1088

Sigma-Aldrich

SRPIN340

≥98% (HPLC)

别名:

(SRPIN)340, N-[2-(1-Piperidinyl)-5-(trifluoromethyl)phenyl]-4-pyridinecarboxamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H18F3N3O
分子量:
349.35
MDL號碼:
分類程式碼代碼:
51111800
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 20 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

O=C(C1=CC=NC=C1)NC2=C(N3CCCCC3)C=CC(C(F)(F)F)=C2

InChI

1S/C18H18F3N3O/c19-18(20,21)14-4-5-16(24-10-2-1-3-11-24)15(12-14)23-17(25)13-6-8-22-9-7-13/h4-9,12H,1-3,10-11H2,(H,23,25)

InChI 密鑰

DWFGGOFPIISJIT-UHFFFAOYSA-N

應用

SRPIN340 has been used as a serine-arginine protein kinase (SRPK) inhibitor to identify if SRPK can phosphorylate the E3 ubiquitin ligase RNF12 ser/arg (SR)-motifs in vivo.

生化/生理作用

SRPIN340 is a cell-permeable, specific and potent inhibitor of Serine-Arginine-Rich Protein Kinase (SRPK) that down-regulates SRp75 and inhibits expression of Sindbis, hepatitis C virus (HCV), HIV, and cytomegalovirus viruses. SRPIN340 appears to be most effective for inhibiting acutely replicating viruses. SRPIN340 suppresses Vegf expression and attenuated choroidal neovascularization (CNV) formation in mice model.
SRPIN340 is an isonicotinamide compound. It protects cardiomyocytes against hydrogen peroxide (H2O2) induced oxidative damage by serine-arginine protein kinase 1/2 (SRPK1/2) inhibition-mediated protein kinase B (AKT) activation.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jian Huang et al.
Biochemical and biophysical research communications, 510(1), 97-103 (2019-01-22)
SRPIN340, a selective serine-arginine protein kinase 1/2 (SRPK1/2) inhibitor, has been shown to have antiviral and anti-angiogenesis effects. However, its role in the heart is unknown. The present study explored the role of SRPIN340 in myocardial protection and the related
Hugues de Boussac et al.
Haematologica, 105(3), 784-795 (2019-07-11)
Multiple myeloma (MM) account for approximately 10% of hematological malignancies and is the second most common hematological disorder. Kinases inhibitors are widely used and their efficiency for the treatment of cancers has been demonstrated. Here, in order to identify kinases
Zhenyu Dong et al.
Molecular vision, 19, 536-543 (2013-04-06)
To investigate the applicability of serine/arginine-rich protein kinase (SRPK)-specific inhibitor, SRPIN340, for attenuation of choroidal neovascularization (CNV) formation using a mouse model. Laser photocoagulation was performed to induce CNV in C57BL/6J mice, followed by intravitreal injection of SRPIN340 or vehicle.
Alzahraa A M Fergany et al.
Recent patents on anti-cancer drug discovery, 15(4), 293-305 (2020-09-10)
RNA splicing, a fundamental step in gene expression, is aimed at intron removal and ordering of exons to form the protein's reading frame. This review is focused on the role of RNA splicing in cancer biology; the splicing abnormalities that
Yuki Takamatsu et al.
mBio, 11(1) (2020-02-27)
Ebola virus (EBOV) causes a severe and often fatal disease for which no approved vaccines or antivirals are currently available. EBOV VP30 has been described as a viral phosphoprotein, and nonphosphorylated VP30 is essential and sufficient to support secondary transcription

商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门